Looking to expand your partner network with leading companies like Curevac? Consider joining Inpart's global network for free.
In Depth 1 Aug 2024
CureVac: From a failed drug to a €1.45 billion deal
In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around.